Sign in Sign up for free

Last updated: 22 February 2023 at 7:20pm EST

Geert Cauwenbergh Net Worth



Geert Cauwenbergh PHIO stock SEC Form 4 insiders trading

Geert has made over 9 trades of the Phio Pharmaceuticals stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of PHIO stock worth $4,500 on 2 October 2017.

The largest trade he's ever made was buying 10,000 units of Phio Pharmaceuticals stock on 2 October 2017 worth over $4,500. On average, Geert trades about 3,333 units every 9 days since 2016. As of 2 October 2017 he still owns at least 142,583 units of Phio Pharmaceuticals stock.

You can see the complete history of Geert Cauwenbergh stock trades at the bottom of the page.





Geert Cauwenbergh biography

Dr. Geert Cauwenbergh, Ph.D. is no longer as Chief Executive Officer, Director of the Company, Effective March 01, 2019. and has been appointed as Director of the company, Effective march 01, 2019. He was appointed to the Board and was elected as President and Chief Executive Officer of the Company in April 2012. Prior to joining us, from June 2011 to April 2012, Dr. Cauwenbergh was active, through his consulting company Phases123 LLC, in advising various small biotech and healthcare companies. From July 2008 to June 2011, Dr. Cauwenbergh was the Chief Executive Officer of Rhei Pharmaceuticals HK Ltd, a Chinese company that licenses western drugs for development and commercialization in China, and Managing Director of the Center for Medical Innovation, a government subsidized center for translational medicine for the Belgian Region of Flanders. Barrier, which focused on dermatology drug development and commercialization, was acquired by Stiefel Laboratories, Inc. in 2008. Prior to founding Barrier, Dr. Cauwenbergh held a number of ascending senior management positions at Johnson & Johnson, where he was employed for 23 years. As Vice President of Research and Development for Johnson & Johnson’s Skin Research Center, he was responsible for the worldwide research and development of all skin care products for the Johnson & Johnson consumer companies. He is a member of the board of directors of Moberg Pharma AB, a Swedish pharmaceutical company. In February 2014, Dr. Cauwenbergh joined the board of directors of Phosphagenics Ltd., an Australian company focused on developing new transdermal delivery systems for pharmaceutical products. Dr. Cauwenbergh currently serves as chairman of the nominating and governance committee of Phosphagenics. In September 2011, Dr. Cauwenbergh also joined the board of directors of Cutanea Life Sciences, Inc., a wholly owned subsidiary of Maruho Company, LTD., which focuses on the development and commercialization of proprietary technologies to treat diseased and aging skin. In 2005,

What is the salary of Geert Cauwenbergh?

As the Director of Phio Pharmaceuticals, the total compensation of Geert Cauwenbergh at Phio Pharmaceuticals is $625,901. There are no executives at Phio Pharmaceuticals getting paid more.



How old is Geert Cauwenbergh?

Geert Cauwenbergh is 65, he's been the Director of Phio Pharmaceuticals since 2019. There are 1 older and 4 younger executives at Phio Pharmaceuticals. The oldest executive at Phio Pharmaceuticals Corp. is H. Paul Dorman, 79, who is the Independent Director.

What's Geert Cauwenbergh's mailing address?

Geert's mailing address filed with the SEC is C/O PHIO PHARMACEUTICALS CORP., 257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH, MA, 01752.

Insiders trading at Phio Pharmaceuticals

Over the last 6 years, insiders at Phio Pharmaceuticals have traded over $0 worth of Phio Pharmaceuticals stock and bought 37,351 units worth $53,368 . The most active insiders traders include Geert Cauwenbergh, Keith L Brownlie, and Patricia A Bradford. On average, Phio Pharmaceuticals executives and independent directors trade stock every 82 days with the average trade being worth of $6,130. The most recent stock trade was executed by Robert J Bitterman on 7 June 2024, trading 1,000 units of PHIO stock currently worth $740.



What does Phio Pharmaceuticals do?

Phio Pharmaceuticals Corp., a biotechnology company, develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on silencing tumor-induced suppression of the immune system. The company develops PH-762 which targets the checkpoint protein PD-1 on immune cells for used in adoptive cell transfer (ACT); PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for used in ACT; and PH-790 which targets PD-L1 protein that keeps immune cells from attacking nonharmful cells in the body. It has collaborations with the Gustave Roussy and Medigene AG, as well as with Helmholtz Zentrum München. Phio Pharmaceuticals has collaboration with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.



What does Phio Pharmaceuticals's logo look like?

Phio Pharmaceuticals Corp. logo

Phio Pharmaceuticals executives and stock owners

Phio Pharmaceuticals executives and other stock owners filed with the SEC include: